REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 10th, 2020 • Assertio Holdings, Inc. • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of May 20, 2020, by and between Assertio Holdings, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
FORM OF COMMON STOCK PURCHASE WARRANT] ASSERTIO HOLDINGS, INC.Common Stock Purchase Warrant • August 10th, 2020 • Assertio Holdings, Inc. • Pharmaceutical preparations • Delaware
This COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time and from time to time after the date hereof (the “Initial Exercise Date”), to subscribe for and purchase from Assertio Holdings, Inc., a Delaware corporation (the “Company”), _________ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
ZYLA LIFE SCIENCES [FORM OF MANAGEMENT CONTINUITY AGREEMENT]Management Continuity Agreement • August 10th, 2020 • Assertio Holdings, Inc. • Pharmaceutical preparations • Delaware
This Management Continuity Agreement (the “Agreement”) is effective as of June 23, 2020 (the “Effective Date”) by and between _______ (“Employee”) and Zyla Life Sciences, a Delaware corporation (the “Company”). This Agreement is intended to provide Employee with certain benefits described herein upon the occurrence of specific events. This Agreement, together with the offer letter between Employee and the Company, dated as of June 23, 2020 (the “Offer Letter”), supersede any other agreement or understanding pertaining to the subject matter herein, existing as of the Effective Date, between the Company or Assertio Holdings, Inc., a Delaware corporation (“Parent”), on the one hand, and Employee on the other hand (any such agreement so superseded is referred to in this Agreement as the “Prior Agreement”).
CERTAIN MATERIAL (INDICATED BY [***]) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCOSED. TRANSITION AND CONSULTING AGREEMENTTransition and Consulting Agreement • August 10th, 2020 • Assertio Holdings, Inc. • Pharmaceutical preparations • Illinois
This Transition and Consulting Agreement (this “Agreement”) is entered into by and between Stanley Bukofzer (“Executive”) and Assertio Therapeutics, Inc., a Delaware corporation (“Assertio”) and is dated as of June 24, 2020 (the “Effective Date”). The Executive and the Company shall collectively be referred to herein as the “Parties.”
EMPLOYMENT AGREEMENTEmployment Agreement • August 10th, 2020 • Assertio Holdings, Inc. • Pharmaceutical preparations • Delaware
THIS EMPLOYMENT AGREEMENT (this "Agreement") is made and entered into as of June 17, 2020 effective as of May 20, 2020 (the "Effective Date"), by and between Zyla Life Sciences, a Delaware corporation (the "Company"), and Todd N. Smith (the "Executive").
